113 related articles for article (PubMed ID: 15504374)
1. Clinical and metabolic aspects of the continuous use of a contraceptive association of ethinyl estradiol (30 microg) and gestodene (75 microg).
Machado RB; Fabrini P; Cruz AM; Maia E; da Cunha Bastos A
Contraception; 2004 Nov; 70(5):365-70. PubMed ID: 15504374
[TBL] [Abstract][Full Text] [Related]
2. A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel.
Skouby SO; Endrikat J; Düsterberg B; Schmidt W; Gerlinger C; Wessel J; Goldstein H; Jespersen J
Contraception; 2005 Feb; 71(2):111-7. PubMed ID: 15707560
[TBL] [Abstract][Full Text] [Related]
3. Effects of two oral contraceptives, containing 30 or 20 microg of ethinyl estradiol in combination with gestodene, on blood coagulation and fibrinolysis in Brazilian women.
Ferreira AC; Montes MB; Franceschini SA; Toloi MR
Int J Fertil Womens Med; 2001; 46(5):265-70. PubMed ID: 11720199
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of lipid profile in adolescents during long-term use of combined oral hormonal contraceptives.
Guazzelli CA; Lindsey PC; de Araújo FF; Barbieri M; Petta CA; Aldrighi JM
Contraception; 2005 Feb; 71(2):118-21. PubMed ID: 15707561
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen.
Sitruk-Ware RL; Menard J; Rad M; Burggraaf J; de Kam ML; Tokay BA; Sivin I; Kluft C
Contraception; 2007 Jun; 75(6):430-7. PubMed ID: 17519148
[TBL] [Abstract][Full Text] [Related]
6. Transdermal contraceptive patch delivering norelgestromin and ethinyl estradiol. Effects on the lipid profile.
Creasy GW; Fisher AC; Hall N; Shangold GA
J Reprod Med; 2003 Mar; 48(3):179-86. PubMed ID: 12698776
[TBL] [Abstract][Full Text] [Related]
7. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of a combined oral contraceptive: gestodene 75 micrograms plus ethinyl estradiol 30 micrograms in Mexican women.
Garza-Flores J; Valles de Bourges V; Martínez M; Vázquez-Estrada L; Bassol S; Recio R; Pérez-Palacios G
Adv Contracept; 1994 Mar; 10(1):19-26. PubMed ID: 8030449
[TBL] [Abstract][Full Text] [Related]
9. Lipoprotein alterations from a triphasic oral contraceptive containing ethinyl estradiol and gestodene. A 12-month trial.
Moutos DM; Zacur HA; Bachorik PS; Wallach EE
J Reprod Med; 1994 Sep; 39(9):720-4. PubMed ID: 7807486
[TBL] [Abstract][Full Text] [Related]
10. [Diabetes regulation and oral contraceptives. Lipoporotein metabolism in women with insulin dependent diabetes mellitus using oral contraceptives].
Petersen KR; Skouby SO; Jepsen PV; Haaber AB
Ugeskr Laeger; 1996 Apr; 158(17):2388-92. PubMed ID: 8685993
[TBL] [Abstract][Full Text] [Related]
11. Prospective, open-label, noncomparative study to assess cycle control, safety and acceptability of a new oral contraceptive containing gestodene 60 microg and ethinylestradiol 15 microg (Minesse).
Barbosa IC; Filho CI; Faggion D; Baracat EC
Contraception; 2006 Jan; 73(1):30-3. PubMed ID: 16371291
[TBL] [Abstract][Full Text] [Related]
12. Effect of a combined oral contraceptive containing 20 microg ethinyl estradiol and 75 microg gestodene on hemostatic parameters.
Aldrighi JM; De Campos LS; Eluf Gebara OC; Petta CA; Bahamondes L
Gynecol Endocrinol; 2006 Jan; 22(1):1-4. PubMed ID: 16522526
[TBL] [Abstract][Full Text] [Related]
13. Serum resistin levels in women taking combined oral contraceptives containing desogestrel or gestodene.
Rechberger T; Tomaszewski J; Pieprzowska-Białek A; Kulik-Rechberger B; Skorupski P
Contraception; 2004 Jun; 69(6):477-80. PubMed ID: 15157792
[TBL] [Abstract][Full Text] [Related]
14. [The effect of two low dose oral contraceptive with gestodene on the systems of natural inhibitors of coagulation].
Uchikova E; Terzhumanov R; Milchev N; Iacheva T
Akush Ginekol (Sofiia); 2004; 43(6):19-23. PubMed ID: 15669648
[TBL] [Abstract][Full Text] [Related]
15. [Laboratory and clinical study with a new progestagen combined with ethinyl estradiol used in contraception].
Galán G; Gayán P; Tisné L
Rev Chil Obstet Ginecol; 1985; 50(4):317-24. PubMed ID: 2953049
[No Abstract] [Full Text] [Related]
16. Effect of two low-dose gestodene containing monophasic oral contraceptives on hemostasis in Bulgarian women.
Uchikova E; Pehlivanov B
Expert Opin Pharmacother; 2008 Aug; 9(11):1839-44. PubMed ID: 18627323
[TBL] [Abstract][Full Text] [Related]
17. Effects of two combined oral contraceptives containing ethinyl estradiol 30 microg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure.
Yildizhan R; Yildizhan B; Adali E; Yoruk P; Birol F; Suer N
Arch Gynecol Obstet; 2009 Aug; 280(2):255-61. PubMed ID: 19125264
[TBL] [Abstract][Full Text] [Related]
18. The effects of two monophasic oral contraceptives containing 30 mcg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters.
Winkler UH; Sudik R
Contraception; 2009 Jan; 79(1):15-23. PubMed ID: 19041436
[TBL] [Abstract][Full Text] [Related]
19. Metabolic profile of a continuous versus a cyclic low-dose combined oral contraceptive after one year of use.
Rad M; Kluft C; de Kam ML; Meijer P; Cohen AF; Grubb GS; Constantine GD; Burggraaf J
Eur J Contracept Reprod Health Care; 2011 Apr; 16(2):85-94. PubMed ID: 21417560
[TBL] [Abstract][Full Text] [Related]
20. The combined contraceptive vaginal ring (NuvaRing) and lipid metabolism: a comparative study.
Tuppurainen M; Klimscheffskij R; Venhola M; Dieben TO
Contraception; 2004 May; 69(5):389-94. PubMed ID: 15105061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
